상세 보기
mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma
- Sangro, B.;
- Kudo, M.;
- Erinjeri, J. P.;
- Qin, S.;
- Ren, Z.;
- ... Tak, W. Y.;
- 외 14명
Citations
WEB OF SCIENCE
1- 제목
- mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma
- 저자
- Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Penagos, F. E.; Chuken, Y. A. Lopez; Yoon, J. H.; Tak, W. Y.; Suttichaimongkol, T.; Bouattour, M.; Lin, S. M.; Zotkiewicz, M.; Ai, S.; Cohen, G. J.; Lencioni, R.
- 발행일
- 2024-10-01
- 유형
- Meeting Abstract
- 권
- 120
- 호
- 2
- 페이지
- E438 ~ E439
- 언어
- ENG
- 출판사
- ELSEVIER SCIENCE INC
- 발행국가
- 미국
- ISSN
- E 1879-355X
P 0360-3016